Program
Metronidazole
Also written as “metronidazole 1% gel”, “Metronidazole Tablet” and “metronidazole”.
Its studies are mostly in Intraabdominal Infections · Vaginosis, Bacterial · Rosacea · Appendicitis · Skin Manifestations, led by 11 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 80 open or running | phase 4since Sep 12, 2005 | Sep 12, 2005 | none ahead |
| Galderma Group | 40 open or running | phase 4since Feb 16, 2007 | Feb 16, 2007 | none ahead |
| S.L.A. Pharma | 40 open or running | phase 3since Jul 30, 2007 | Jul 30, 2007 | none ahead |
| Curatek Pharmaceuticals | 20 open or running | phase 3since Dec 1, 2014 | Dec 1, 2014 | none ahead |
| Par Health | 20 open or running | phase 1since Jun 16, 2011 | Jun 16, 2011 | none ahead |
| Teva Pharmaceutical Industries | 20 open or running | phase 2since Nov 24, 2009 | Nov 24, 2009 | none ahead |
| appili-therapeutics-inc | 10 open or running | phase 1since Nov 6, 2017 | Nov 6, 2017 | none ahead |
| biorasi-llc | 10 open or running | phase 3since Mar 12, 2015 | Mar 12, 2015 | none ahead |
| Dr. Reddy's Laboratories | 10 open or running | phase 2since Mar 19, 2012 | Mar 19, 2012 | none ahead |
| Insud Pharma | 10 open or running | phase 4since Mar 4, 2015 | Mar 4, 2015 | none ahead |
| Saptalis Pharmaceuticals | 11 open or running | phase 2since Aug 8, 2025 | Aug 8, 2025 | none ahead |
Also a collaborator on its studies: allergan-sales-llc, AbbVie, algorithme-pharma-inc and pricara-unit-of-ortho-mcneil-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 12 studies since Sep 12, 2005.
- Jul 20, 2011Phase 1 study in InfectionsPfizer · NCT01407016 · 6 enrolled · Japan
- Aug 26, 2011Phase 4 study in RosaceaGalderma Group · NCT01426269 · 235 enrolled · United States
- Oct 11, 2011Phase 3 study in Intraabdominal InfectionsPfizer · NCT01473836 · 38 enrolled · Japan
- Dec 19, 2011Phase 3 study in Complicated Intra-Abdominal InfectionPfizer · NCT01499290 · 493 enrolled · United States, Argentina, Bulgaria and more
- Feb 9, 2012Phase 1 study in HealthyPfizer · NCT01534247 · 28 enrolled · United States
- Mar 19, 2012Dr. Reddy's Laboratories's first study: phase 2 study in Clostridium Difficile Associated DiarrheaNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT01559545 · 60 enrolled · India
- Nov 5, 2012Phase 3 study in Complicated Intra-abdominal InfectionPfizer · NCT01726023 · 486 enrolled · China, Korea, Republic of, Vietnam
- Dec 1, 2014Curatek Pharmaceuticals's first studies: 2 phase 3 studies in VaginitisNew to Curatek PharmaceuticalsCuratek Pharmaceuticals · NCT02308033, NCT02308007
- Mar 4, 2015Insud Pharma's first study: phase 4 study in Vaginosis, BacterialNew to Insud PharmaInsud Pharma · NCT02392026 · 60 enrolled · United States
- Mar 12, 2015biorasi-llc's first study: phase 3 study in RosaceaNew to biorasi-llcbiorasi-llc · NCT02393937 · 963 enrolled · United States
- May 25, 2015Phase 2 study in Complicated Intra-abdominal InfectionsPfizer · NCT02475733 · 83 enrolled · United States, Czechia, Greece and more
- Nov 6, 2017appili-therapeutics-inc's first study: phase 1 study in BioequivalenceNew to appili-therapeutics-incappili-therapeutics-inc · NCT03337126 · 48 enrolled · Canada
- Jan 15, 2020Phase 2 study in Pilonidal SinusS.L.A. Pharma · NCT04273997 · 80 enrolled · Turkey
- Aug 8, 2025Saptalis Pharmaceuticals's first study: phase 2 study in Bacterial InfectionsNew to Saptalis PharmaceuticalsSaptalis Pharmaceuticals · NCT07146217 · 30 planned · United States
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“DNA inhibitor; DNA inhibitor”ChEMBL 37, by rule
Studies
All 27 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07146217Bacterial Infections · United States | 2 | Not yet recruiting | Saptalis Pharmaceuticals | Jul 2026 | 30 |
| NCT04273997Pilonidal Sinus · Turkey | 2 | UNKNOWN | S.L.A. Pharma | Feb 1, 2022 | 80 |
| NCT03337126Bioequivalence · Canada | 1 | Completed | appili-therapeutics-inc | Dec 13, 2017 | 48 |
| NCT02475733Complicated Intra-abdominal Infections · United States, Czechia, Greece and more | 2 | Completed | Pfizer | Jun 1, 2017 | 83 |
| NCT02393937Rosacea · United States | 3 | Completed | biorasi-llc | Jul 2015 | 963 |
| NCT02392026Vaginosis, Bacterial · United States | 4 | Completed | Insud Pharma | Oct 5, 2016 | 60 |
| NCT02308033Vaginitis · United States | 3 | Completed | Curatek Pharmaceuticals | Jun 2017 | 204 |
| NCT02308007Vaginitis · United States | 3 | Completed | Curatek Pharmaceuticals | Jun 2018 | 475 |
| NCT01726023Complicated Intra-abdominal Infection · China, Korea, Republic of, Vietnam | 3 | Completed | Pfizer | Mar 2015 | 486 |
| NCT01559545Clostridium Difficile Associated Diarrhea · India | 2 | Completed | Dr. Reddy's Laboratories | Feb 2013 | 60 |
| NCT01534247Healthy · United States | 1 | Completed | Pfizer | Jul 2012 | 28 |
| NCT01499290Complicated Intra-Abdominal Infection · United States, Argentina, Bulgaria and more | 3 | Completed | Pfizer | Apr 2014 | 493 |
| NCT01473836Intraabdominal Infections · Japan | 3 | Completed | Pfizer | Oct 2012 | 38 |
| NCT01426269Rosacea · United States | 4 | Completed | Galderma Group | Jun 2013 | 235 |
| NCT01407016Infections · Japan | 1 | Completed | Pfizer | Sep 2011 | 6 |
| NCT01380522Lecithin Cholesterol Acyltransferase Deficiency · Canada | 1 | Completed | Par Health | Sep 2002 | 18 |
| NCT01380509Fasting · Canada | 1 | Completed | Par Health | Sep 2002 | 28 |
| NCT01139047Skin Manifestations · United States | 4 | Completed | Galderma Group | Jun 2010 | 77 |
| NCT01139008Skin Manifestations · United States | 4 | Completed | Galderma Group | Jun 2010 | 80 |
| NCT01020877Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Nov 2001 | 38 |
| NCT01020396Vaginosis, Bacterial · United States | 2 | Completed | Teva Pharmaceutical Industries | Mar 2003 | 579 |
| NCT00774969Perianal Crohns' · United Kingdom | 1 | Completed | S.L.A. Pharma | Apr 2008 | 19 |
| NCT00774722Haemorrhoidectomy · United Kingdom | 3 | Completed | S.L.A. Pharma | Mar 2008 | 59 |
| NCT00509639Crohn Disease · United States, United Kingdom | 3 | Completed | S.L.A. Pharma | Feb 2008 | 74 |
| NCT00436527Rosacea · United States | 4 | Completed | Galderma Group | Aug 2006 | 26 |
| NCT00230971Appendicitis · Australia, China, Denmark and more | 4 | Completed | Pfizer | Sep 2008 | 473 |
| NCT00195351Appendicitis · United States, Argentina, Brazil and more | 4 | Completed | Pfizer | Feb 2008 | 467 |
How it is read
Names in the registry
- “Metronidazole”, 20 entries
- “metronidazole 1% gel”, 2 entries
- “Metronidazole Tablet”, 2 entries
- “metronidazole”, 2 entries
- “Likmez® (metronidazole) Oral Suspension”, 1 entry
Conditions, from the studies’ own filings
- Intraabdominal Infections, 7 studies
- Vaginosis, Bacterial, 4 studies
- Rosacea, 3 studies
- Appendicitis, 3 studies
- Skin Manifestations, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.